Edition:
United Kingdom

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

25.40USD
16 Feb 2018
Change (% chg)

$0.75 (+3.04%)
Prev Close
$24.65
Open
$24.59
Day's High
$25.49
Day's Low
$24.51
Volume
57,120
Avg. Vol
75,162
52-wk High
$28.62
52-wk Low
$18.67

Chart for

About

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials... (more)

Overall

Beta: 2.15
Market Cap(Mil.): $1,163.30
Shares Outstanding(Mil.): 46.93
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus

* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS

05 Jan 2018

BRIEF-Xencor Receives Milestone Payment From Amgen

* SAYS IT HAS EARNED A $10 MILLION MILESTONE PAYMENT FROM AMGEN

05 Dec 2017

BRIEF-Xencor posts Q3 loss of $0.33 per share

* Xencor reports third quarter 2017 financial results and provides clinical pipeline update

07 Nov 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.26 +0.55
Novartis AG (NOVN.S) CHF80.42 -0.38
Roche Holding Ltd. (ROG.S) CHF224.30 -1.20
Roche Holding Ltd. (RO.S) CHF229.00 -1.20
AstraZeneca plc (AZN.L) 4,766.50 +27.00
GlaxoSmithKline plc (GSK.L) 1,321.80 +3.20
AbbVie Inc (ABBV.N) $118.60 +3.70
Bristol-Myers Squibb Co (BMY.N) $68.96 -0.02
Bristol-Myers Squibb Co (BMYMP.PK) $1,042.55 --
Amgen, Inc. (AMGN.OQ) $183.55 -0.05

Earnings vs. Estimates